在HFpEF中,阿德罗宾可以保护心脏代谢重塑和功能障碍
bioRxiv : the preprint server for biology
|July 14, 2025
概括
在小鼠中,阿德罗类激素治疗逆转了心力衰竭,并保留了喷射分数 (HFpEF) 标记. 它通过调节新陈代谢和减少O-GlcNAcylation来改善心脏功能,这表明HFpEF的新治疗方法.
科学领域:
- 心脏病学 心脏病学
- 代谢疾病 代谢疾病
- 分子生物学分子生物学
背景情况:
- 心脏代谢性心力衰竭与保存的喷射分数 (HFpEF) 是一种复杂的代谢障碍,其特征是心脏的透静功能障碍,硬和重塑.
- 心脏代谢功能障碍是HFpEF病理生理学的关键驱动因素,目前的治疗旨在纠正这些缺陷.
研究的目的:
- 在心脏代谢HFpEF的临床前模型中研究潜在的心脏功能障碍的分子机制.
- 评估复合阿德罗宾在逆转高血压相关心脏缺陷方面的治疗潜力.
主要方法:
- 使用了心脏代谢HFpEF的临床前小鼠模型.
- 用复合阿德罗进行长期治疗.
- 进行非目标代谢分析以分析代谢变化.
- 评估心脏功能的标志物,包括纤维化,腹功能障碍和心肌细胞缩.
主要成果:
- 阿德罗治疗显著逆转了与HFpEF相关的心脏功能障碍的多种标志物.
- 代谢分析显示Adropin限制了代谢物进入六胺生物合成途径.
- 这种限制导致长链乙-CoA脱酶的O-GlcNAcylation减少,这是一个关键的心脏脂肪酸氧化酶.
结论:
- 阿德罗在HFpEF中显示出恢复心脏代谢功能的潜力.
- 针对赫索胺生物合成途径和O-GlcNAcylation,为HFpEF提供了一个新的治疗策略.
相关概念视频
Heart Failure V: Medical Management
27
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
27
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
513
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
513
Heart Failure II: Pathophysiology
46
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
46
Heart Failure Drugs: Diuretics
496
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
496
Heart Failure VI: Adjunct Therapies
31
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
31
Cardiomyopathy V: Interprofessional Care
37
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
37


